Table 2.
Concomitant therapy during each rituximab cycle with patient outcomes.
| Cycle | No. patients | No. patients receiving concomitant steroid dose | Mean concomitant steroid dose per day | No. patients receiving adjuvant* | No. patients in CROT | No. patients in CRMT | Relapsed |
|---|---|---|---|---|---|---|---|
| 1st | 19 | 19/19 (100%) | 31 mg | 16/19 (84.2%) | 2/19 (10.5%) | 6/19 (31.5%) | 44.4% |
| 2nd | 7 | 7/7 (100%) |
21 mg | 4/7 (57.1%) |
1/7 (14.3%) | 6/7 (85.7%) | 42.8% |
| 3rd | 3 | 3/3 (100%) |
16 mg | 1/3 (33.3%) |
0/3 | 3/3 (100%) | 0% |
*Azathioprine 100 mg/day.